Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2012 by King Faisal Specialist Hospital & Research Center.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Dr. Naeem A. Chaudhri, King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:
NCT00535509
First received: September 24, 2007
Last updated: April 16, 2012
Last verified: April 2012

September 24, 2007
April 16, 2012
June 2007
June 2013   (final data collection date for primary outcome measure)
Efficacy [ Time Frame: overall ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00535509 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer
Not Provided

Phase II trial of Neoadjuvant [FEC100]/Cisplatin-Docetaxel ± Trastuzumab in women with over expressed or amplified Her2/Neu with Locally advanced Breast Cancer

Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Breast Cancer
  • Radiation: Cisplatin-Docetaxel ± Trastuzumab
    Chemo & RT
  • Other: Cisplatin-Docetaxel ± Trastuzumab
    Chemo & RT
  • Drug: Cisplatin-Docetaxel ± Trastuzumab
    Chemo & RT
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
285
June 2013
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with locally advanced breast cancer
Female
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00535509
RAC #2061-048
No
Dr. Naeem A. Chaudhri, King Faisal Specialist Hospital & Research Center
King Faisal Specialist Hospital & Research Center
Not Provided
Principal Investigator: Taher Twegieri, MD KFSH&RC
Study Director: Dahish Ajarim, MD KFSH&RC
King Faisal Specialist Hospital & Research Center
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP